NCT07605520招募中1 期
An Experimental Medicine Multicenter Trial to Evaluate the Safety and Immunogenicity of Experimental Versus Authorized SARS-CoV-2 Vaccine Candidates as a Booster Dose in Healthy Participants Previously Vaccinated With Authorized mRNA SARS-CoV-2 Vaccines.
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 48
- 试验地点
- 3
研究概览
简要总结
The SOLVE-01 trial is a study evaluating four SARS-CoV-2 vaccines as booster injections: two experimental vaccines (CD40.RBDv and CD40.Pan.CoV, both combined with the Hiltonol® adjuvant) and two authorised vaccines (Comirnaty® and NuvaxovidTM). This trial is designed for healthy adults aged 18 to 65 at the time of signing the informed consent form.
The main objectives of this trial are:
- to evaluate the safety of the two experimental vaccines,
- to determine the antibody response induced by the vaccines and its durability.
Participants will:
- Receive one injection of vaccine and two intradermal skin tests
- Come to the hospital 10 visits for medical exams and blood and saliva sample collection
- Keep a diary of their symptoms and the treatments taken
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Male and female subjects aged 18 to 65 years inclusive at the time of the screening visit
- •Having received at least two doses of COVID-19 mRNA vaccines in the past with the last dose received more than 6 months prior to IMP administration in the trial
- •In healthy condition or with stable health status which is defined as an existing disease that has not required a significant change in treatment or hospitalization for worsening before enrolment, and for which neither a significant change in treatment or hospitalization for worsening is expected in the near future.
- •For woman of childbearing potential: a negative Beta-HCG blood test measure during the screening visit, and a negative highly sensitive pregnancy urinary test the day of the vaccination visit
- •if heterosexually active female, consistently using a highly effective method of contraception with partner from at least 21 days prior to enrolment through 4 months after the IMP administration. Highly effective contraception is defined as using any of the following methods:
- •Combined hormonal contraception with inhibition of ovulation (estrogen and progesterone containing);
- •Intrauterine device (IUD);
- •Intrauterine hormone releasing system (IUS);
- •Hormonal contraception (progesterone only);
- •Successful vasectomy in the male partner (considered successful if a participant reports that a male partner has (i) documentation of azoospermia by microscopy, or (ii) a vasectomy more than 2 years ago with no resultant pregnancy despite unprotected sexual activity post vasectomy);
- •Or not be of reproductive potential, such as having reached menopause (no menses for 1 year without an alternative medical cause) or having undergone hysterectomy, bilateral oophorectomy, or tubal ligation.
- •Agree not to seek pregnancy including through alternative methods, such as artificial insemination or in vitro fertilization until 4 months after the IMP administration.
- •Participant who was born male, if heterosexually active male, using an effective method of contraception with their partner from the IMP administration until 4 months thereafter. All male participants also agree not to donate sperm during this period.
- •Negative nasopharyngeal antigenic test for SARS-CoV-2 on the day of screening and before randomisation
- •Participant who has normal biological values:
- •Hemoglobin ≥ 11.0 g/dL for participants who were born female, ≥ 13.0 g/dL for participants who were born male;
- •White blood cell count = 3,300 to 12,000 cells/mm3;
- •Total lymphocyte count ≥ 800 cells/mm3;
- •Platelets = 125,000 to 550,000/mm3;
- •ALT, AST, and alkaline phosphatase < 1.25 times the institutional upper limit of normal;
- •Creatinine <1.1x institutional upper limit of normal of the laboratory;
- •Normal urine test: absence of glucose, protein and haemoglobin
- •Negative HIV antigen/antibody test;
- •Negative Hepatitis B surface antigen (HBsAg);
- •Negative anti-Hepatitis C virus antibodies (anti-HCV), or negative HCV polymerase chain reaction (PCR) if the anti-HCV is positive;
- •Willingness to undertake SARS-CoV-2 testing according to study protocol, and receive SARS-CoV-2 test results
- •Willingness and availability to be followed for the planned duration of the study in one of the dedicated trial centres
- •Informed and signed written consent form before performance of any trial-related screening procedures
- •Agree to be registered in the French Health Ministry computerised file (for France only)
- •Being covered by Health Insurance (for France only)
排除标准
- •Acute febrile infection (body temperature ≥ 38.0°C) within the previous 72 hours and/or presenting symptoms suggestive of COVID-19 or SARS-CoV-2 infection within the previous 28 days or having been in contact with an infected individual for the last 14 days before the inclusion visit
- •Any medical condition that could impair the immune response: clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. A clinically significant condition or process includes but is not limited to:
- •A process that would affect the immune response;
- •A process that would require medication that affects the immune response;
- •Any contraindication to repeated injections or blood draws;
- •A condition that requires active medical intervention or monitoring to avert grave danger to the participant's health or well-being during the study period;
- •A condition or process for which signs or symptoms could be confused with reactions to vaccine, or
- •Any condition specifically listed among the exclusion criteria below.
- •Pregnancy or breastfeeding that is currently ongoing, or positive pregnancy test at screening visit and the day of the vaccination
- •Immunodeficiency
- •Asthma: a condition that requires active medical intervention or monitoring to avert grave danger to asthma other than mild, well-controlled asthma. (Symptoms of asthma severity as defined in the most recent National Asthma Education and Prevention Program (NAEPP) Expert Panel report). Exclude a participant who:
- •Uses a short-acting rescue inhaler (typically a beta 2 agonist) daily, or
- •Uses moderate/high dose inhaled corticosteroids, or
- •In the past year has either of the following: (i) Greater than 1 exacerbation of symptoms treated with oral/parenteral corticosteroids or (ii) Needed emergency care, urgent care, hospitalization, or intubation for asthma.
- •Diabetes type 1 or type 2, including cases controlled with diet alone. (Not excluded: history of isolated gestational diabetes).
- •Thyroidectomy, or thyroid disease requiring medication during the last 12 months
- •Hypertension:
- •If a person has been diagnosed with hypertension, exclude for blood pressure that is not well controlled (well-controlled blood pressure is defined as consistently ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic, with or without medication, with only isolated, brief instances of higher readings, which must be ≤ 150 mm Hg systolic and ≤ 100 mm Hg diastolic). For these participants, blood pressure must be ≤ 140 mm Hg systolic and ≤ 90 mm Hg diastolic at enrolment;
- •If a person has NOT been diagnosed with hypertension, exclude for systolic blood pressure ≥ 150 mm Hg at enrolment or diastolic blood pressure ≥ 100 mm Hg at enrolment. (the measurement must be performed on a person who has been lying down for at least 5 minutes and repeat at the end of the consultation, if appropriated). Tension must be confirmed outside the clinical site to rule out hypertension.
- •Contraindication to the IMPs including hypersensitivity
- •BMI ≥ 40 kg/m2; ≤ 18 kg/m2; or BMI ≥ 35 kg/m2 with 2 or more of the following: age > 45, systolic blood pressure > 140 mm Hg, diastolic blood pressure > 90 mm Hg, current smoker, known hyperlipidemia
- •Bleeding disorder diagnosed (e.g., coagulation factor deficiency, coagulopathy, or platelet disorder requiring special precautions)
- •Malignancy (Not excluded: volunteer who has had malignancy excised surgically and who, in the investigator's estimation, has a reasonable assurance of sustained cure, or who is unlikely to experience recurrence of malignancy during the period of the study)
- •Asplenia: any condition resulting in the absence of a functional spleen
- •Seizure disorder: History of seizure(s) within past three years. Also excluded if volunteer has used medications in order to prevent or treat seizure(s) at any time within the past 3 years.
- •History of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
- •History of myocarditis, pericarditis, cardiomyopathy, congestive heart failure with permanent sequelae, clinically significant arrhythmia (including arrhythmia requiring medication, treatment, or clinical follow-up)
- •History of autoimmune disease
- •Any medical, psychiatric, occupational, or other condition that, in the judgment of the investigator, would interfere with or serve as a contraindication to protocol adherence, assessment of safety, or a volunteer's ability to give informed consent
- •Psychiatric condition that precludes compliance with the protocol. Specifically excluded are persons with psychoses within the past 3 years, ongoing risk for suicide, or history of suicide attempt or gesture within the past 3 years.
- •History of serious adverse reactions to vaccines including anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain. (Not excluded: a volunteer who had a non-anaphylactic adverse reaction to pertussis vaccine as a child)
- •Investigational research agents received within 30 days before IMP administration
- •Experimental vaccine(s) received within the last 5 years in a prior vaccine trial
- •Live attenuated vaccines (e.g., measles, mumps, and rubella (MMR); oral polio vaccine (OPV); varicella; yellow fever) received within 30 days before IMP administration or scheduled within 28 days after the injection scheduled within the protocol
- •Vaccines that are not live attenuated vaccines and were received within 21 days prior to IMP administration (e.g., tetanus, pneumococcal, Hepatitis A or B)
- •Blood-derived products or immunoglobulin received within 6 months before IMP administration*
- •Current anti-tuberculosis (TB) prophylaxis or therapy received within 3 months before IMP administration *
- •Allergy treatment with antigen injections within 30 days before IMP administration or that are scheduled within 14 days after IMP administration*
- •Immunosuppressive medications or immunomodulators (such as cytokines or interferons) received within last three months before IMP administration. (Not excluded: (1) corticosteroid nasal spray; [2] topical corticosteroids for mild, uncomplicated dermatitis; or (2) a single course of oral/parenteral corticosteroids at doses < 2 mg/kg/day and length of therapy < 11 days with completion at least 30 days prior to enrolment) or low dose oral corticosteroids (≤10 mg prednisone/day) or corticosteroids for the treatment of immune-related adverse events*
- •Other prohibited medications: Corticosteroids > 10 mg prednisone equivalent/day (not excluded: topical preparations) *
- •Person participating in another research involving the human person or participating in another research involving the human person with an exclusion period still in progress at screening
- •Intent to participate in another study of an investigational research agent during the planned duration of the study
- •Participants who are not able to understand and to follow all required study procedures for the whole period of the study in the judgment of the investigator
- •Under tutorship (only for France), guardianship, or deprived of liberty by a juridical or administrative decision
- •Planned absence that could affect participation in the study (travel abroad, relocation, impending professional mutation...)
- •The scheduled use of these treatments up to 6 months after the injection also represents a contraindication
研究者
研究点 (3)
Loading locations...
相似试验
进行中（未招募）
1 期
Effect of COV2 Vaccine Formulation on the Ability to Generate Antibodies Against Coronavirus That Causes COVID-19NCT07416539Rokote Laboratories Finland Oy20
进行中（未招募）
4 期
Effectiveness of mRNA-1273 Variant-Containing Vaccine Formulation Against Severe Outcomes in Adults Aged 50-64 Years Without Risk Factors for Severe COVID-19NCT07279766Tor Biering-Sørensen285,000
尚未招募
不适用
A Post-Approval Multicenter Study to Assess the Continued Safety and Effectiveness of the AeroPace® SystemNCT07477054Lungpacer Medical Inc.120
Unknown
不适用
航空地勤人员接种新型冠状病毒肺炎(COVID-19)灭活疫苗安全性和免疫原性的随机对照研究ChiCTR2100041705重大传染性疾病防控与诊治山西省重点实验室资助；山西省“新冠肺炎”财政资助专项360
Unknown
不适用
安全保障人员接种新型冠状病毒肺炎(COVID-19)灭活疫苗安全性和免疫原性的随机对照研究ChiCTR2100041706重大传染性疾病防控与诊治山西省重点实验室资助；山西省“新冠肺炎”财政资助专项360